OncoMatch/Clinical Trials/NCT06795022
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
Is NCT06795022 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including AZD9793 Intravenous (IV) monotherapy and AZD9793 Subcutaneous (SC) monotherapy) for hepatocellular carcinoma.
Treatment: AZD9793 Intravenous (IV) monotherapy · AZD9793 Subcutaneous (SC) monotherapy) — This research is designed to determine if experimental treatment with AZD9793, a T cell-engaging antibody that targets GPC3, is safe, tolerable and has anti-cancer activity in patients with advanced or metastatic solid tumours which are GPC3+.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Biomarker criteria
Required: GPC3 positive tumour as determined by a central laboratory using an analytically validated IHC assay
GPC3 positive tumour as determined by a central laboratory using an analytically validated IHC assay
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy — HCC
Patients who have received at least one prior line of standard systemic therapy for HCC as per National Comprehensive Cancer Network or other local scientific guidelines
Cannot have received: CAR-T cell therapy
Exception: within the last 6 months prior to enrolment
CAR-T cell therapy within the last 6 months prior to enrolment on this study
Cannot have received: GPC3-targeted therapy
Prior treatment with any therapy that is targeted to GPC3
Lab requirements
Blood counts
Adequate organ and bone marrow function measured within 28 days prior to first dose as defined by the protocol
Kidney function
Adequate organ and bone marrow function measured within 28 days prior to first dose as defined by the protocol
Liver function
Child-Pugh Score class A
Cardiac function
Cardiac conditions as defined by the protocol [excluded]
Child-Pugh Score class A. Adequate organ and bone marrow function measured within 28 days prior to first dose as defined by the protocol. Cardiac conditions as defined by the protocol [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · La Jolla, California
- Research Site · Los Angeles, California
- Research Site · Baltimore, Maryland
- Research Site · St Louis, Missouri
- Research Site · Hackensack, New Jersey
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify